Capital’s greed to maximize profits respects very few boundaries. If the pharmaceutical industry were to be used as an example, it would seem that greed that is predicated on the helplessness of the sick and the ailing knows no bounds at all. Recent evidence for this comes from the marketing of a drug, called Sovaldi, by the US based company, Gilead. Sovaldi has quickly gained notoriety for being the ‘1,000 dollar pill’.
Gilead commenced marketing of Sovaldi in 2013, and its sales in the first quarter of 2014 had already touched $3.48 billion. Many predict that the annual sale of Sovaldi will outstrip that of the biggest block-buster drug ever – Pfizer’s Liptor (generic name Atorvastatin -- a drug to reduce lipid le...
Also read: Trump gives Petraeus a pass